The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.
Gary J. Schiller
Research Funding - Ambit BioSciences
Martin S. Tallman
No relevant relationships to disclose
Stuart L. Goldberg
Research Funding - Ambit BioSciences
Alexander E. Perl
Consultant or Advisory Role - Ambit BioSciences (U); Astellas Pharma (U)
Jean-Pierre Marie
No relevant relationships to disclose
Giovanni Martinelli
No relevant relationships to disclose
Richard A. Larson
Research Funding - Ambit BioSciences
Nigel Russell
No relevant relationships to disclose
Denise Trone
Employment or Leadership Position - Ambit BioSciences
Guy Gammon
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
Mark J. Levis
Consultant or Advisory Role - Ambit BioSciences (U)
Jorge E. Cortes
Consultant or Advisory Role - Ambit BioSciences (U); Astellas Pharma (U)
Research Funding - Ambit BioSciences; Astellas Pharma